RC48
Sponsors
RemeGen Co., Ltd., RenJi Hospital, The First Affiliated Hospital with Nanjing Medical University, Fudan University, Tianjin Medical University Second Hospital
Conditions
CDK12 Gene MutationGC/GEJCGastric Cancer/Gastroesophageal Junction AdenocarcinomaHER2Mammary or Extramammary Paget's DiseaseNon Small Cell Lung CancerNon-Muscle Invasive Bladder CancerProstate Cancer
Phase 1
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
CompletedNCT04311034
Start: 2018-09-26End: 2022-05-30Updated: 2023-12-18
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
RecruitingNCT06663007
Start: 2024-09-24End: 2027-08-31Target: 72Updated: 2024-10-29
Phase 2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RecruitingNCT05957757
Start: 2023-08-05End: 2026-06-08Target: 20Updated: 2023-08-31
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Not yet recruitingNCT06385873
Start: 2024-05-01End: 2028-05-01Target: 32Updated: 2024-05-13
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
RecruitingNCT06561555
Start: 2024-08-15End: 2027-08-15Target: 36Updated: 2024-12-17
The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC
Not yet recruitingNCT07172217
Start: 2025-10-01End: 2028-12-31Target: 33Updated: 2025-09-15
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
RecruitingNCT07474324
Start: 2026-03-15End: 2030-12-31Target: 124Updated: 2026-03-16